US FDA panel backs approval for Eisai-Biogen Alzheimer's drug Leqembi

US FDA panel backs approval for Eisai-Biogen Alzheimer's drug Leqembi Leqembi won accelerated approval by the FDA in January based on its ability to remove sticky amyloid plaques from the brain. The panel on Friday considered Eisai's large confirmatory trial designed to show the drug benefited patients. https://ift.tt/0NfGR1m

Comments

Post a Comment

Popular posts from this blog

SC transfers PIL seeking implementation of law on mental health care to NHRC

The PIL argued that persons with mental illnesses were chained in a faith-based mental asylum in Budaun district of Uttar Pradesh in violation of provisions of the Mental Health Care Act 2017. The court examined the photos of such patients calling it a matter of great concern. from Top Health News | Latest Healthcare Sector & Healthcare Industry news, Information and Updates: ET HealthWorld : ETHealthworld.com https://ift.tt/hG1drmq via gqrds
Read more

Hospital-insurer conflict: Will latest circular by NMC help in reducing the pain of health insurance policyholders?

The rational use of medicines and diagnostics will directly benefit policyholders by lowering their out-of-pocket expenses. At the same time, streamlined care will result in faster recovery and fewer complications, believes Roy. from Top Health News | Latest Healthcare Sector & Healthcare Industry news, Information and Updates: ET HealthWorld : ETHealthworld.com https://ift.tt/OG5T7Mw via gqrds
Read more

Over 9.19 crore hospital admissions facilitated under Ayushman Bharat since 2018

According to the National Health Authority's (NHA) annual report 2024-25, over 40.45 crore Ayushman cards were issued till March 31, covering 14.69 crore families and eighty-two per cent of beneficiaries are from rural areas, with 94 per cent having Aadhaar-verified cards, ensuring authenticity and inclusivity, the report stated. from Top Health News | Latest Healthcare Sector & Healthcare Industry news, Information and Updates: ET HealthWorld : ETHealthworld.com https://ift.tt/JRnLlcK via gqrds
Read more